Cite
HARVARD Citation
Li, X. et al. (2021). A pharmacophore‐based classification better predicts the outcomes of HER2‐negative breast cancer patients receiving the anthracycline‐ and/or taxane‐based neoadjuvant chemotherapy. Cancer medicine. pp. 4658-4674. [Online].